Completed PHASE4 INTERVENTIONAL 2-arm NCT00299221

Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients (TICTAC)

Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients

Sponsor: Astellas Pharma Inc

Conditions Immunosuppression

Interventions Tacrolimus combination therapy

Updated 8 times since 2017 Last updated: May 26, 2015 Started: Apr 30, 2004 Primary completion: Jun 30, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Immunosuppression, this trial is completed. The trial is conducted by Astellas Pharma Inc and has accumulated 8 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Dec 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Newark Beth Israel Medical Center

Data source: Newark Beth Israel Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States
• Newark, United States